Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.
NCT ID: NCT07329686
Last Updated: 2026-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
100 participants
INTERVENTIONAL
2025-10-01
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
NCT03128463
VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)
NCT01249664
Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
NCT02357342
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
NCT04520321
Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers
NCT04685369
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group
The experimental group received intrastromal corneal injections of anti-VEGF (Vascular Endothelial Growth Factor) medication in conjunction with antiviral medication therapy.
Intrastromal anti-VEGF injection and topical antiviral eye drops
The experimental group received intrastromal corneal injections of anti-VEGF (Vascular Endothelial Growth Factor) medication in conjunction with antiviral medication therapy
Control group
The control group was treated with conventional antiviral topical ocular drops.
Conventional antiviral topical ocular drops.
The control group was treated with conventional antiviral topical ocular drops.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intrastromal anti-VEGF injection and topical antiviral eye drops
The experimental group received intrastromal corneal injections of anti-VEGF (Vascular Endothelial Growth Factor) medication in conjunction with antiviral medication therapy
Conventional antiviral topical ocular drops.
The control group was treated with conventional antiviral topical ocular drops.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: Adults aged 18 years or older.
* Previous Treatment: Patients who have not undergone other anti-VEGF treatments or corneal surgeries.
* Informed Consent: Patients who are capable of understanding and signing an informed consent form, agreeing to participate in the entire study process and to follow the study's follow-up schedule and treatment plan.
* Other: Additional criteria as deemed necessary by the investigator.
Exclusion Criteria
* Severe Ocular Surface Dryness: Patients with severe dry eye syndrome.
* Systemic Diseases: Patients with systemic diseases that may affect the nervous or immune systems, such as diabetes, rheumatoid arthritis, autoimmune diseases, etc.
* Recent Use of Systemic Immunosuppressants: Patients who have recently used systemic immunosuppressive agents.
* Poor Compliance: Patients who are unable to follow up on time or adhere to the treatment plan.
* Pregnancy or Lactation: Pregnant or nursing women, as their physiological state may affect study outcomes.
* Allergy History: Patients with a history of allergies to the study medication or related components.
* Other Reasons: Patients deemed by the investigator to have other reasons making them unsuitable for participation in the trial.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
1 Xihu Avenue, Shangcheng District,Hangzhou, Zhejiang,China,Hangzhou, Zhejiang Completed
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-0998
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.